Analysis of 131 cases of COVID-19 treated with Ganlu Xiaodu Decoction
(2.Chinese Medicine Integrative Oncology Department, China-Japan Friendship Hospital, Beijing 100029)
(3.Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029)
(4.Department of Pain Rehabilitation, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430060)
【Abstract】In this study, DtHealth Hospital Information Management System and PASS PharmAssist (Medicom) were used to collect the medical records of all inpatients diagnosed as coronavirus disease 2019 (COVID-19) in Wuhan Third Hospital. The statistics were based on the data of the cases treated with Ganlu Xiaodu Decoction, including demographic statistics, clinical characteristics before medication, the outcome after medication, and efficacy of combined medication. Excel 2003 and SPSS Clementine 12.0 software were used to conduct statistics on the included cases, and the Apriori algorithm and association rules were used for the association analysis on combined medication. A total of 131 cases of COVID-19 were treated with Ganlu Xiaodu Decoction combined with Chinese and Western medicine. All of the patients were cured and discharged. The drug combination mainly included Ganlu Xiaodu Decoction, abidor, Lianhua Qingwen, moxifloxacin, Qiangli Pipa Distillate, vitamin C, diammonium glycyrrhizinate, pantoprazole, and Shufeng Jiedu. There was a certain regularity and effectiveness in the treatment of COVID-19 infection patients with the combination of Ganlu Xiaodu Decoction and other drugs, but the rationality and safety still needed to be further verified.
【Keywords】 COVID-19; 2019-nCoV; Ganlu Xiaodu Decoction; combined medication; association;
(Translated by ZHAO B)
 National Health Commission of China. The World Health Organization has announced the COVID-19 epidemic as a public health emergency of international concern [EB/OL]. [2020-03-16]. http://www.nhc.gov.cn/xcs/s3574/202002/3fdf885083e5470090728ede3c7f7e4b.shtml/2020-01-31 (in Chinese).
 Office of the National Health Commission of China, Office of the National Administration of Traditional Chinese Medicine of China. Notice on printing and distributing the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) [EB/OL]. (2020-03-04)[2020-03-16]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9a7dfe4cef80dc7f5912eb1989.shtml (in Chinese).
 YUE D H, Sun J, Bi Y. The original purpose of Ganlu Xiaodu Pills and its clinical application [J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2015, 21 (12): 1586 (in Chinese).
 PANG W T, JIN X Y, PANG B, et al. Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19 [J]. China Journal of Chinese Materia Medica, 2020, 45 (6): 1242 (in Chinese).
 QI X J, ZHOU R J, LIU H P, et al. Analysis on regularity of traditional Chinese patent medicine in treating hyperlipidemia [J]. China Journal of Chinese Materia Medica, 2019, 44 (19): 4277 (in Chinese).
 HUO X Q, HU R J, ZHANG X L. A clinical study on Ganlu Xiaodu Pill as an adjuvant agent in treatment of geriatric pneumonia with dampness-heat congesting the lung [J]. Chinese Journal of Clinical Rational Drug Use, 2019, 12 (7): 80 (in Chinese).
 WEI S C, YUE D H, YU L H, et al. Research overview of Ganlu Xiaodu Pills in treating disease with syndrome of damp-heat [J]. Clinical Journal of Traditional Chinese Medicine, 2017, 29 (5): 735 (in Chinese).
 WANG J. Discussion on the original purpose of Ganlu Xiaodan Pellet [J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2014, 20 (4): 438 (in Chinese).
 FAN Z W, Li Y Z, YANG J Y. Treatment of three cases of cough and asthma with Ganlu Xiaodan Pellet by Professor Duzhou Liu [J]. Guangming Journal of Chinese Medicine, 2013, 28 (12): 16 (in Chinese).
 WANG Y, DING Y, YANG C, et al. Inhibition of the infectivity and inflammatory response of influenza virus by arbidol hydrochloride in vitro and in vivo (mice and ferret) [J]. Biomed Pharmacother, 2017, 91: 393.
 LI Y, ZHAO L. Research status on pharmacological actions and in vitro and in vivo effects of arbidol against respiratory viruses [J]. The Chinese Journal of Clinical Pharmacology, 2019, 35 (17): 1964 (in Chinese).
 CAO Y. Observations on the safety and efficacy of arbidol hydrochloride tablets in the treatment of acute respiratory tract viral infections [J]. Chinese Journal of Modern Drug Application, 2018, 12 (17): 101 (in Chinese).
 Guan W D, Du Q L, Jiang H M, et al. Comparison of inhibitory effects of arbidol and Lianhuaqingwen Capsules on Middle East respiratory syndrome coronavirus in vitro and in vivo [J]. Guangdong Medical Journal, 2018, 39 (23): 3454 (in Chinese).
 JI X G, ZHAO Y H, ZHANG M, et al. The experimental study of the anti-SARS-CoV effect of arbidol [J]. Pharmaceutical Journal of Chinese People’s Liberation Army, 2004, 20 (4): 274 (in Chinese).
 WANG T, HAN L F, WANG Y F, et al. Recent advances in treatment of viral pneumonia using Chinese patent medicine [J]. China Journal of Chinese Materia Medica, 2020, 45 (7): 1509 (in Chinese).
 CUI W W, JIN X, ZHANG Y F et al. Effects of Lianhua Qingwen Capsules on IKK/IκB/NF-κB signal pathway in the mouse with LPS-induced acute lung injury [J]. Chinese Traditional Patent Medicine, 2015, 37 (5): 953 (in Chinese).
 YAO K T, LIU M Y, LI X, et al. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, doi: 10.13422/j.cnki.syfjx.20201099 (in Chinese).
 BAO Y Y, GAO Y J, SHI Y J, et al. Study on Broad-spectrum antiviral effect of Shufeng Jiedu Capsules [J]. Journal of New Chinese Medicine, 2019, 51 (12): 5 (in Chinese).
 MA L, HUANG Y, HOU Y B, et al. Anti-inflammatory mechanism of Shufeng Jiedu Capsules in rat pneumonia model [J]. Chinese Traditional and Herbal Drugs, 2018, 49 (19): 124 (in Chinese).
 LIU J, MA L, LU J, et al. Study on mechanism for antipyretic effects of Shufeng Jiedu Capsule [J]. Chinese Traditional and Herbal Drugs, 2016, 47 (12): 2040 (in Chinese).
 Ma L, Huang Y, Hou Y B, et al. Study on mechanism for immunoregulation of Shufeng Jiedu Capsule [J]. Drug Evaluation Research, 2019, 42 (9): 1769 (in Chinese).
 CAO L F, TANG C, XIA J et al. Observation on the therapeutic effect of Shufeng Jiedu Capsule on AECOPD complicated with pulmonary infection [J]. Journal of Emergency in Traditional Chinese Medicine, 2019, 28 (9): 1636 (in Chinese).
 Zhang L L. Study on the clinical effect of moxifloxacin in the treatment of pulmonary infection [J]. Journal of North Pharmacy, 2020, 17 (1): 120 (in Chinese).
 JIANG Z. Observation on the therapeutic effect of Qiangli Pipa Syrup combined with azithromycin in the treatment of mycoplasma pneumonia [J]. Nei Mongol Journal of Traditional Chinese Medicine, 2017, 36 (13): 61 (in Chinese).
 LI H W. Observation on the clinical efficacy of Qiangli Pipa Syrup combined with ambroxol in the treatment of chronic bronchitis [J]. Modern Diagnosis and Treatment, 2019, 30 (22): 3901 (in Chinese).
 YANG H, DONG Z L, Nadira Abuliz, et al. Analysis of the therapeutic effect of vitamin C as an adjuvant in the treatment of secondary pulmonary tuberculosis [J]. Guide of China Medicine, 2020, 18 (1): 91 (in Chinese).
 LI X, LIN Z H. Observation on the clinical therapeutic effect of Xiaoer Chiqiao Qingre Granules in combination with vitamin C tablets in the treatment of hand, foot, and mouth disease [J]. Journal of North Pharmacy, 2019, 16 (12): 78 (in Chinese).
 CHEN X F. Value of Vitamin C Injection combined with Reduning Injection in children with hand, foot, and mouth disease [J]. World Latest Medicine Information, 2019, 19 (97): 377 (in Chinese).
 BU M Q. Observation on the clinical therapeutic effect of high-dose vitamin C combined with Xiaoer Ganmaoling in the treatment of viral upper respiratory tract infection in children [J]. Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine, 2019, 7 (3): 159 (in Chinese).
 SUN J. Clinical study of diammonium glycyrrhizinate enteric-coated capsules in the prevention of liver damage [J]. Genomics and Applied Biology, 2016, 35 (8): 1899 (in Chinese).
 XIE X L, CHEN S F, SHEN W P. Effect of pantoprazole sodium enteric-coated tablets on ulcer healing quality and MMP and TIMP-1 levels in patients with gastric ulcer [J/OL]. International Infections Diseases (Electronic Edition), [2020-02-26]. http://kns.cnki.net/kcms/detail/11.9314.R.20200226.0922.188.html (in Chinese).
 JI Y Y. Observation on the efficacy and safety of pantoprazole for the treatment of peptic ulcer with upper gastrointestinal bleeding [J]. Jilin Medical Journal, 2020, 41 (3): 628 (in Chinese).
 MA S Y. Comparison of clinical effects of pantoprazole and omeprazole in treatment of patients with duodenal ulcers [J]. Jilin Medical Journal, 2020, 41 (2): 339 (in Chinese).
 WANG L. Analysis of the therapeutic effect of pantoprazole combined with ulinastatin in the treatment of acute pancreatitis [J]. Journal of Qiannan Medical College for Nationalities, 2019, 32 (4): 255 (in Chinese).
 CHEN J, LIU D P, LIU L et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 [J/OL]. Journal of Zhejiang University (Medical Sciences) [2020-03-09]. http://kns.cnki.net/kcms/detail/33.1248.R.20200309.1507.006.html (in Chinese).
 LIU Y, SU N, CHEN Z Y et al. Literature analysis on efficacy and safety of chloroquine phosphate in infectious diseases [J/OL]. Herald of Medicine, [2020-03-06]. http://kns.cnki.net/kcms/detail/42.1293.R.20200306.1015.002.html (in Chinese).
 ZHANG Q. Analysis of adverse reactions in the combined use of traditional Chinese and Western medicines in outpatient pharmacy [J]. Journal of China Prescription Drug, 2016, 14 (5): 24 (in Chinese).
 ZHANG D, LV J T, ZHANG B et al. Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19 [J]. China Journal of Chinese Materia Medica, 2020, 45 (10): 2275 (in Chinese).